Gilead Sciences (CH:GILD)
NASDAQ:GILD
GILD Stock Chart & Stats
CHF108.81
CHF0.00(0.00%)
Market closed
CHF108.81
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF67.87 - CHF121.37
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
CHF135.16B
Enterprise ValueCHF191.36B
Total Cash (Recent Filing)CHF10.61B
Total Debt (Recent Filing)CHF24.59B
Price to Earnings (P/E)17.9
Beta0.13
Next Earnings
Apr 23, 2026EPS Estimate
1.48Next Dividend Ex-DateN/A
Dividend Yield2.64%
Share Statistics
EPS (TTM)1.46
Shares Outstanding1,241,222,000
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)6.75
Price to Sales (P/S)5.19
P/FCF Ratio16.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF124.94Price Target Upside14.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)6.5
Revenue Forecast (FY)CHF23.68B
Bulls Say, Bears Say
Bulls Say
HIV Franchise And Prevention Uptake Support RevenueStrong uptake of Yeztugo combined with continued leadership in HIV treatment provides a stable revenue base and potential upside if prevention use broadens beyond analyst expectations.
Lead Asset Clinical Promise In Ovarian CancerEarly clinical data for the lead antibody‑drug conjugate showed encouraging responses and a tolerable safety profile in platinum‑resistant ovarian cancer, supporting plans for a registrational trial.
Strategic Acquisition Expands Oncology CapabilitiesAcquisition of Tubulis expands oncology and antibody‑drug conjugate capabilities, creating synergies with existing drug‑conjugate programs and leveraging the prior partnership to reduce execution risk.
Bears Say
Clinical And Regulatory UncertaintyEarly‑stage clinical datasets and limited durability data for oncology candidates increase clinical and regulatory uncertainty that could delay or derail commercialization.
Integration And Management Distraction RiskMultiple recent acquisitions may strain management resources and distract from execution on core programs, increasing integration risk.
Rising Costs And Leverage PressureElevated selling and administrative expenses, sizable in‑process research charges, and increased leverage could weigh on margins and limit financial flexibility.
Gilead Sciences News
GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was CHF67.87 and its highest was CHF121.37 in the past 12 months.
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is CHF135.16B.
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Apr 23, 2026 which is in 8 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Feb 10, 2026. The company reported CHF1.457 earnings per share for the quarter, beating the consensus estimate of CHF1.418 by CHF0.039.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of CHF0.71 which represents an annual dividend yield of 2.64%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is 1.48.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,241,222,000 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of CHF1.457 in its last earnings report, beating expectations of CHF1.418. Following the earnings report the stock price went up 2.943%.
Which hedge fund is a major shareholder of Gilead Sciences?
Currently, no hedge funds are holding shares in CH:GILD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gilead Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF124.94 (14.83% Upside)
CHF124.94 (14.83% Upside)
Blogger Sentiment
Bullish
CH:GILD Sentiment 70%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.72%
12-Months-Change
Fundamentals
Return on Equity
41.01%
Trailing 12-Months
Asset Growth
0.05%
Trailing 12-Months
Company Description
Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD Company Deck
GILD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial execution (notably in HIV treatment and prevention, liver, and Trodelvy) and a robust, diversified late-stage pipeline with multiple near-term catalysts and disciplined financial management. These positives were balanced against clear near-term headwinds: policy-driven pricing impacts (Part D/Medicaid/ACA), a substantial decline in COVID-related Vecluri revenue, and competitive pressures in cell therapy expected to reduce Kite revenues in 2026. Management reiterated conservative discipline on M&A and continued commitment to shareholder returns. Overall, company achievements, pipeline momentum, and outperformance against guidance materially outweigh the headwinds, which are largely known, quantified, and described as manageable.View all CH:GILD earnings summariesGILD Revenue Breakdown
70.48% HIV
10.93% Liver Disease
3.09% Veklury
10.99% Oncology
2.71% Other
1.79% Royalty, contract and other revenues
GILD Stock 12 Month Forecast
Average Price Target
CHF124.94
▲(14.83% Upside)
Technical Analysis
Options Prices
Currently, No data available
---